PRIMARY CARE ADULT WOMAN II 2026
CERTIFICATION EVALUATION EXAM
QUESTIONS AND ANSWERS MASTER FILE
◉ Intermediate Duration Insulin. Answer: NPH insulin (Humulin N,
Novolin N)
◉ Long Duration Insulin. Answer: Insulin glargine (U-100) (Lantus);
Insulin Detemir (Levemir)
◉ Ultralong Duration. Answer: Insulin glargine (U-300) (Toujeo);
Insulin degludec (Tresiba)
◉ Drugs for Asthma and Chronic Obstructive Pulmonary Disease.
Answer: antiinflammatory agents and bronchodilators.
◉ principal anti-inflammatory drugs for asthma/COPD. Answer:
glucocorticoids
◉ principal bronchodilators for asthma/COPD. Answer: β2 agonists
,◉ 1st Step Therapy for Asthma Treatment. Answer: SABA PRN
◉ 2nd Step Therapy For Asthma Treatment. Answer: SABA PRN +
Low dose IGC
◉ 3rd Step Therapy For Asthma Treatment. Answer: Ages 0-4: SABA
PRN + Medium-dose IGC
Ages 5-Adult: SABA PRN + Low-dose IGC + LABA or LTRA or
theophylline OR Medium-dose IGC
◉ 4th Step Therapy For Asthma Treatment. Answer: Ages 0-11:
SABA PRN + Medium-dose IGC plus
LABA or montelukast
Ages 12-Adult: Medium-dose IGC + LABA
◉ 5th Step Therapy For Asthma Treatment. Answer: Ages 0-4: SABA
PRN + High-dose IGC + LABA or Montelukast
Ages 5-11: SABA PRN + High-dose IGC +
LABA
,Ages 12-Adult: SABA PRN + High-dose IGC + LABA
AND consider omalizumab for patients with allergies
◉ 6th Step Therapy For Asthma Treatment. Answer: Ages 0-4: SABA
PRN + High-dose IGC + LABA/montelukast + Oral glucocorticoids
Ages 5-11: SABA PRN + High-dose IGC + LABA +
Oral glucocorticoids
Ages 12-Adult: High-dose IGC + LABA + Oral glucocorticoids and
Consider omalizumab for patients with allergies
◉ Asthma Severity Classification Domains. Answer: Impairment and
Risk.
◉ Impairment. Answer: effect of asthma on quality of life and
functional capacity in the present
◉ Risk. Answer: possible adverse events in the future, such as
exacerbations and progressive loss of lung function.
, ◉ Intermittent Asthma (Initial Treatment). Answer: Symptoms
2d/week or less; SABA use 2d/week or less; No effect on activity--
>Step 1 Treatment
◉ Mild Persistent Asthma (Initial Treatment). Answer: Symptoms
more than 2 d/wk but less than daily; SABA use more than 2 d/wk
but less than daily; Minimal Activity Limitation-->Step 2 Treatment
◉ Moderate Persistent Asthma (Initial Treatment). Answer:
Symptoms daily. Some limited activity; Weekly nighttime
awakenings.
◉ Severe Persistent Asthma (Initial Treatment). Answer: Symptoms
several times daily; Severe activity limitation
Ages 0-4: Step 3 Treatment
Ages 5-11: Step 4 Treatment
Ages 12-Adult: Step 4 or 5 Treatment
◉ Well Controlled Asthma. Answer: Continue current therapy.
Reevaluate in 1-6 months.
May step down after control well maintained for 3 months.
◉ Not Well Controlled Asthma (0-4 y/o). Answer: Step up therapy
by 1 step.
CERTIFICATION EVALUATION EXAM
QUESTIONS AND ANSWERS MASTER FILE
◉ Intermediate Duration Insulin. Answer: NPH insulin (Humulin N,
Novolin N)
◉ Long Duration Insulin. Answer: Insulin glargine (U-100) (Lantus);
Insulin Detemir (Levemir)
◉ Ultralong Duration. Answer: Insulin glargine (U-300) (Toujeo);
Insulin degludec (Tresiba)
◉ Drugs for Asthma and Chronic Obstructive Pulmonary Disease.
Answer: antiinflammatory agents and bronchodilators.
◉ principal anti-inflammatory drugs for asthma/COPD. Answer:
glucocorticoids
◉ principal bronchodilators for asthma/COPD. Answer: β2 agonists
,◉ 1st Step Therapy for Asthma Treatment. Answer: SABA PRN
◉ 2nd Step Therapy For Asthma Treatment. Answer: SABA PRN +
Low dose IGC
◉ 3rd Step Therapy For Asthma Treatment. Answer: Ages 0-4: SABA
PRN + Medium-dose IGC
Ages 5-Adult: SABA PRN + Low-dose IGC + LABA or LTRA or
theophylline OR Medium-dose IGC
◉ 4th Step Therapy For Asthma Treatment. Answer: Ages 0-11:
SABA PRN + Medium-dose IGC plus
LABA or montelukast
Ages 12-Adult: Medium-dose IGC + LABA
◉ 5th Step Therapy For Asthma Treatment. Answer: Ages 0-4: SABA
PRN + High-dose IGC + LABA or Montelukast
Ages 5-11: SABA PRN + High-dose IGC +
LABA
,Ages 12-Adult: SABA PRN + High-dose IGC + LABA
AND consider omalizumab for patients with allergies
◉ 6th Step Therapy For Asthma Treatment. Answer: Ages 0-4: SABA
PRN + High-dose IGC + LABA/montelukast + Oral glucocorticoids
Ages 5-11: SABA PRN + High-dose IGC + LABA +
Oral glucocorticoids
Ages 12-Adult: High-dose IGC + LABA + Oral glucocorticoids and
Consider omalizumab for patients with allergies
◉ Asthma Severity Classification Domains. Answer: Impairment and
Risk.
◉ Impairment. Answer: effect of asthma on quality of life and
functional capacity in the present
◉ Risk. Answer: possible adverse events in the future, such as
exacerbations and progressive loss of lung function.
, ◉ Intermittent Asthma (Initial Treatment). Answer: Symptoms
2d/week or less; SABA use 2d/week or less; No effect on activity--
>Step 1 Treatment
◉ Mild Persistent Asthma (Initial Treatment). Answer: Symptoms
more than 2 d/wk but less than daily; SABA use more than 2 d/wk
but less than daily; Minimal Activity Limitation-->Step 2 Treatment
◉ Moderate Persistent Asthma (Initial Treatment). Answer:
Symptoms daily. Some limited activity; Weekly nighttime
awakenings.
◉ Severe Persistent Asthma (Initial Treatment). Answer: Symptoms
several times daily; Severe activity limitation
Ages 0-4: Step 3 Treatment
Ages 5-11: Step 4 Treatment
Ages 12-Adult: Step 4 or 5 Treatment
◉ Well Controlled Asthma. Answer: Continue current therapy.
Reevaluate in 1-6 months.
May step down after control well maintained for 3 months.
◉ Not Well Controlled Asthma (0-4 y/o). Answer: Step up therapy
by 1 step.
